Immunomodulating Therapy Of Sepsis

Objective To observe therapeutic effect by treating the CLP rat with Ulinastatin and Thymosin α1 together, and to study the feasibility of immunomodulating therapy for sepsis.Methods Use classic CLP sepsis model of rat. All the animals were divided into 4 groups randomly: control group, combined medicine group (Ulinastatin and Thymosin α1 ), Ulinastatin group and Thymosin α1 group. Each group had 36 rats. Medicines were injected through tail vein or by hypodermic at 6 hours, 24 hours, 48 hours and 72 hours after the models were established. The blood samples were taken to test TNFα , IL-6, IL-10, WBC and MHC-II~+/CD14~+ level at 24 hours, 48 hours, 72 hours and 96 hours after the models were established. Record the mortality rate every day. The data were assessed by the statistic Chiss software. Measurement data were demonstrated by x±s and analyzed by F test (P<0.05 was significantly different). Mortality rates were analyzed by chi square test (P<0.05 was significantly different).Results 1. Compared with normal rats, some data of CLP rats were different.. TNF α level was increased at the second and third day. IL-6 level was increased at the first day. IL-10 level was increased at the first, second and third day. MHC-II~+/CD14~+ level was decreased during the whole experiment period. The differences were significant. 2. The total mortality rate at the third and forth day in combined medicine group was decreased significantly. 3. After treatment, MHC-II~+ /CD14~+ level at the second day in combined medicine group was increased significantly. 4. After treatment, TNFα level at the second day in combined medicine group decreased significantly, and there was insignificant difference of IL-6 and IL-10 level between each group. 5. In pathology morphous, organs' damage was most severe in control group, slightest in combined medicine group and slighter in single medicine groups.Conclusions 1. CLP sepsis model represents double conditions with both systemic inflammation response accentuation and immunosuppression. 2. The prognosis was improved significantly in combmed medicine group. 3. Combined Medicine can lessen inflammation response and improve immunosuppression. 4. Combined medicine was most efficient to lessen organs' damage. 5. Treating sepsis by the method of both antiinflammation and immunomodulating with combination of Ulinastatin and Thymosin α1 was rational.